- Home
- CYCN vs ADXN Comparison
CYCN vs ADXN Comparison
Compare CYCN & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | ADXN |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 10.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYCN | ADXN |
|---|---|---|
| Price | $1.35 | $7.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.6K | 7.2K |
| Earning Date | 11-12-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,855,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1371.65 | N/A |
| 52 Week Low | $1.28 | $6.51 |
| 52 Week High | $6.25 | $12.05 |
Technical Indicators
Market Signals| Indicator | CYCN | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 32.47 | 48.25 |
| Support Level | $1.43 | $7.48 |
| Resistance Level | $1.51 | $8.90 |
| Average True Range (ATR) | 0.11 | 0.48 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 0.69 | 51.85 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.